RecruitingPhase 4ketamine

Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes

Sponsored by Peking University First Hospital

NCT ID
NCT06087510
Target Enrollment
312 participants
Start Date
2024-01-24
Est. Completion
2026-09

About This Study

Chronic postsurgical pain (CPSP) refers to pain that occurs or increases after surgery and lasts longer than 3 months. Severe acute postoperative pain is one of the major risk factors of CPSP. Spinal correction surgery is associated with severe pain due to large trauma and long duration. Ketamine and esketamine are N-methyl-D-aspartate receptor antagonists; they have antihyperalgesic effects and may reduce CPSP. Dexmedetomidine is an alpha 2-adrenoceptor agonist with sedative, anxiolytic, and analgesic effect; it is frequently used as an adjuvant to postoperative analgesia. In a previous trial of 200 patients after scoliosis correction surgery, mini-dose esketamine-dexmedetomidine in combination with opioids significantly improved analgesia and sleep quality but did not reduce CPSP. The authors speculate that increasing esketamine dose in the combination may further improve analgesia and, therefore, reduce the occurrence of CPSP.

Conditions Studied

Scoliosis CorrectionPostoperative AnalgesiaEsketamineDexmedetomidineChronic Postsurgical Pain

Interventions

  • Esketamine

Eligibility

Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Patients aged ≥18 years and body weight≥40 kg;
* Scheduled to undergo scoliosis correction with pedicle screw fixation;
* Required patient-controlled intravenous analgesia (PCIA) after surgery.

Exclusion Criteria:

* Preoperative sick sinus syndrome, severe sinus bradycardia (heart rate \<50 beats per minute), atrioventricular block grade II or above without pacemaker, congenital heart disease, arrhythmia, or other serious cardiovascular diseases with a New York Heart Association class ≥III;
* Patients with moderate or severe obstructive sleep apnea diagnosed preoperatively or according to the STOP-Bang score;
* History of hyperthyroidism or pheochromocytoma;
* History of schizophrenia, epilepsy, myasthenia gravis;
* Severe liver dysfunction (Child-Pugh grade C), severe renal dysfunction (preoperative dialysis), or American Society of Anaesthesiologists grade ≥IV;
* Barrier in communication;
* Other conditions that were considered unsuitable for study participation.

Study Locations (1)

Beijing University First Hospital
Beijing, Beijing Municipality, China

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Dong-Xin Wang, MD, PhD
CONTACT
8610-83572784wangdongxin@hotmail.com
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source

Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes | Huxley